Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02434666 · ClinicalTrials.gov registry record · Phase 2
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
A Phase 2 study of Dementia of the Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 5
- Study locations
NCT02434666 is a Phase 2 study of Dementia of the Alzheimer's Type that has completed, run by Chase Pharmaceuticals Corporation, an affiliate of Allergan. The registered enrollment target is 21 participants. The trial reports 5 study locations across 3 states.
The verdict
NCT02434666, a Phase 2 study of Dementia of the Alzheimer's Type, has completed, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).
Conditions Studied
Interventions
- DRUG CPC-201
Study Locations (5)
Florida
- Miami Jewish Health Systems - Miami
- Quantum Laboratories, Inc. Memory Disorder Center - Pompano Beach
- Premiere Research Institute Neuroscience - West Palm Beach
Indiana
- IU School of Medicine IU Health Neuroscience Center - Indianapolis
North Carolina
- Giles Cromwell, MD - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-01-08 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02434666
The ClinicalTrials.gov registry entry for NCT02434666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dementia of the Alzheimer's Type appearing as the primary indexed condition, and to 1 intervention - of which CPC-201 is the first listed.
NCT02434666 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02434666 about?
NCT02434666 is a clinical study titled "Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07". This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).
What is the current status of trial NCT02434666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2015-01-08. Estimated completion is 2016-11-22.
What conditions does trial NCT02434666 study?
This clinical trial studies the following conditions: Dementia of the Alzheimer's Type.
What interventions are being tested in trial NCT02434666?
The interventions under investigation include: CPC-201 (DRUG).
Who is sponsoring clinical trial NCT02434666?
This trial is sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02434666 being conducted?
This trial has 5 study locations across Florida, Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.